





Thursday, August 4, 2016
7:00 – 8:00 AM USA Eastern Daylight Time
1:00 – 2:00 PM European Central Time
4:30 – 5:30 PM India Standard Time
7:00 – 8:00 PM China Standard Time
8:00 – 9:00 PM Japan/Korea Standard Time

The Toxicologic Pathology of Common Kinase Targets

Hosted by IFSTP Co-sponsored by IATP and STP-I

This webinar will cover common toxicities associated with inhibition of cellular kinases by small molecule pharmaceuticals. The human kinome is rich with targets for anticancer and immunomodulatory therapies and this presents an opportunity for toxicologists and pathologists to help the broader medical community by characterizing the roles that kinases play in tissue function. The goal of the presentation is to shed light on some of the tissue responses associated with common kinase targets, and to highlight future opportunities in understanding the role kinases play in health and disease.

Dr. LaBranche is currently the head toxicology and pathology at Blueprint Medicines, which develops highly selective and potent kinase inhibitors for patients with genomically defined diseases and previously worked at Pfizer. Dr. LaBranche received his veterinary and graduate degrees at Virginia Tech in Blacksburg, VA and residency in pathology at University of Georgia.



Speaker
Timothy LaBranche DVM, PhD, DACVP
Senior Director
Blueprint Medicines
Cambridge, MA

Webinar Registration is Free, but space is limited!

Please visit the IFSTP website at www.ifstp.net to register for the webinar. You must preregister by August 1st. Space is limited to 100 attendees and is available on a first-come, first-serve basis. Please allow one week for your registration to be processed. Once your registration is approved, you will receive an email from the IFSTP office with instructions on how to join the webinar.

Deadline to Register is Monday, August 1, 2016

For registration or technical questions, please contact IFSTP at ifstp-hq@verizon.net
This webinar will be available for future viewing on www.ifstp.net